{"title":"BIA-ALCL diagnosis: the relevance of cytology and flow cytometry in periprosthetic fluid analysis.","authors":"Radu Chiriac, Marie Donzel, Lucile Baseggio","doi":"10.1684/abc.2025.1976","DOIUrl":"https://doi.org/10.1684/abc.2025.1976","url":null,"abstract":"<p><p>Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell non-Hodgkin lymphoma, representing less than 1% of breast neoplasms. Despite its low incidence, the increasing number of women with breast implants necessitates vigilance among clinicians and pathologists. BIA-ALCL presents in situ and invasive forms, with varying prognoses. The National Comprehensive Cancer Network guidelines recommend cytology, immunohistochemistry, and flow cytometry (FCM) for diagnosis. This retrospective study analyzed 16 periprosthetic fluid (PF) samples from suspected lymphoma cases between January 2018 and January 2024. Cytological and immunological analyses were performed using May Grünwald-Giemsa staining, and FCM with BD FACSCanto II and BD LYRIC cytometers. A 10 or 12-colour FCM panel including pan-T markers and CD30 was used. Of the 16 samples, 2 cases were diagnosed with BIA-ALCL. BIA-ALCL cases showed atypical CD4+ T-cells with large size and loss of CD3 and CD7. In contrast, the 14 reactive cases did not exhibit atypical cells. Key challenges included sample volume limitations, cell dilution, and distinguishing neoplastic cells from reactive ones, particularly in cases with low cell counts. FCM, combined with an extensive panel of pan-T markers and CD30, effectively differentiates anaplastic BIA-ALCL cells from reactive seroma. However, it should complement, not replace, traditional diagnostic methods. Recognizing pitfalls and correlating FCM findings with clinical and morphological data enhances diagnostic accuracy. FCM is a valuable tool for diagnosing BIA-ALCL but should be used alongside other methods. Accurate diagnosis depends on understanding sample-specific challenges and integrating FCM results with clinical context.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"83 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Vérification des performances de la méthode COBAS® AmpliPrep/COBAS® TaqMan HIV-1 test, v 2.0 pour la quantification de la charge virale plasmatique du VIH-1.","authors":"Ella Christelle Brou, Aboubakar Touré, Fidèle Sounan Touré, Eugénie Yaudé, Inza Dosso, Marcellin Konan, Durand Sery, Christiane Kiki-Barro","doi":"10.1684/abc.2025.1972","DOIUrl":"https://doi.org/10.1684/abc.2025.1972","url":null,"abstract":"<p><p>The laboratory of the National Institute of Public health makes HIV-1 plasma RNA quantification. That test is required to follow up HIV patient on ART (Antiretroviral therapy). The laboratory was accredited by the West African Accreditation System (SOAC) in 2022 for HIV real time PCR. Here we report the experience of the laboratory for verifiying performance of the COBAS® AmpliPrep/COBAS® TaqMan (CAP/CTM) HIV-1 test, v 2.0 kit for measuring viral load by real time PCR. According with the technical guides of the French Accreditation Committee (COFRAC) and the recommendations of the French Society of Clinical Biology (SFBC), different steps were followed. These are the risk assessment, the study of reliability, intermediate precision, accuracy and precision of the method, estimation of measurement uncertainty and comparison of methods. Coefficient of variation for repeatability, reproducibility and trueness were within target of 5 %. The results from the CAP/CTM were reproductible and identical to those of the COBAS 6800. The COBAS® AmpliPrep/COBAS® TaqMan HIV-1 Test, v 2.0 method is suitable for routine laboratory use and has analytical performance for its intended utility, which mean the assessment of disease progression and monitoring of antiretroviral therapy for HIV-1 patients.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"83 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexandre Leonard, Benjamin Bonnet, Carolyne Croizier, Bertrand Evrard, Vincent Sapin, Anne Fogli, Damien Bouvier
{"title":"[Studying daratumumab's interference in serum protein electrophoresis: two case reports].","authors":"Alexandre Leonard, Benjamin Bonnet, Carolyne Croizier, Bertrand Evrard, Vincent Sapin, Anne Fogli, Damien Bouvier","doi":"10.1684/abc.2025.1963","DOIUrl":"10.1684/abc.2025.1963","url":null,"abstract":"<p><p>An 86-year-old woman is monitored for IgA λ-associated multiple myeloma, treated in second intention with dexamethasone, revlimid and daratumumab after a relapse. A control serum protein electrophoresis detects the presence of a new monoclonal spike, later confirmed by immunofixation as an IgG κ. Suspecting an interference due to the immunotherapy, a daratumumab specific immunofixation reflex assay (DIRA) is performed, with the addition of anti-daratumumab antibodies, confirming the interference. A second multiple myeloma case is presented, describing interference with daratumumab co-migrating with the original monoclonal immunoglobulin. Based on these cases, we propose an algorithm of action to confirm the interference and provide an accurate biological result consistent with the therapeutic and clinical context.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"83 2","pages":"202-10"},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ying Yang, Linxin Zhang, Xing Zhao, Juan Li, Qingping Chen, Yaya Gao, Jun Yan
{"title":"Evaluation of the prognostic value of coagulation function and cerebral hemodynamic changes in acute ischemic stroke patients with rheumatoid arthritis.","authors":"Ying Yang, Linxin Zhang, Xing Zhao, Juan Li, Qingping Chen, Yaya Gao, Jun Yan","doi":"10.1684/abc.2025.1965","DOIUrl":"10.1684/abc.2025.1965","url":null,"abstract":"<p><p>To explore the relationship between early coagulation changes, cerebral hemodynamics, and neurological prognosis in acute ischemic stroke (AIS) patients with rheumatoid arthritis (RA). Seventy-two AIS patients with RA were included. Coagulation markers (PT, APTT, FIB) and transcranial Doppler ultrasound (TCD) assessments of middle cerebral artery (MCA) mean velocity (Vm) and pulsatility index (PI) were measured at baseline and after 14 days of treatment. Prognosis was evaluated using the modified Rankin Scale (mRS) at 3 months, dividing patients into good (mRS ≤ 2) and poor prognosis (mRS > 3) groups. Multivariate logistic regression and ROC analysis assessed the predictive value of coagulation and hemodynamic changes for adverse outcomes. After 14 days, APTT and MCA (PI) increased, while FIB decreased in both groups (P < 0.05). The good prognosis group had higher MCA Vm and lower FIB at baseline (P < 0.05). Independent risk factors for poor prognosis included diabetes, NIHSS score ≥ 8, FIB, and MCA (Vm, PI) (P < 0.05). ROC analysis showed combined FIB, Vm, and PI had better predictive value for poor outcomes. Early hypercoagulable state and suboptimal cerebral hemodynamics are associated with poor neurological outcomes in AIS with RA.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"83 2","pages":"185-94"},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paul Billoir, Sébastien Miranda, Hervé Lévesque, Ygal Benhamou, Véronique Le Cam Duchez
{"title":"[Usefulness of the thrombin generation test in hypercoagulability states].","authors":"Paul Billoir, Sébastien Miranda, Hervé Lévesque, Ygal Benhamou, Véronique Le Cam Duchez","doi":"10.1684/abc.2025.1955","DOIUrl":"10.1684/abc.2025.1955","url":null,"abstract":"<p><p>Thrombin is one of the key components of the hemostatic system. The thrombin generation assay (TGA) assesses the activation, propagation and inhibition of coagulation. This global coagulation test is of interest for assessing the risk of bleeding and thrombosis. Numerous studies have been performed in the \"thrombophilia\". We performed a systematic review of studies on thrombinography in thrombophilia. The included studies, published in English, were original investigations using TGT during venous thromboembolic disease, arterial occlusive pathology, pregnancy, anti-phospholipid syndrome, constitutional thrombophilias, or oncology. Eighty studies were selected between January 2003 and June 2022. Most had fewer than 100 patients. The only two studies that included more than 1000 patients showed an increased risk of thrombotic recurrence or increased mortality from cardiovascular disease associated with increased thrombin generation. All \"thrombophilia\" have been studied, but lack of standardization between conditions has limited the development of clinical research with this assessment technique. Harmonization of practices may provide more relevant systems for predicting the occurrence of arterial or venous thrombotic events.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"83 2","pages":"121-46"},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[O negative blood for everyone? No, transfusion and obstetrical management of a pregnant woman with an anti-public H1I1 antibody].","authors":"Maud Gilson, Anaïs Devey","doi":"10.1684/abc.2025.1962","DOIUrl":"10.1684/abc.2025.1962","url":null,"abstract":"<p><p>A woman pregnant with her first child, blood group B+, showed pan-agglutination on antibody identification panels during her pregnancy follow-up. The absence of agglutination between the patient's plasma and a panel of B-phenotype red blood cells led to the conclusion of the presence of an anti-H1I1. This antibody is not thought to be responsible for fetal anemia or neonatal hemolytic disease, thus follow-up of fetal anemia is not necessary. However, in the event of transfusion, prior compatibility with blood of the same ABO group is necessary. In emergencies, group O depot blood should not be used whenever possible.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"83 2","pages":"223-6"},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Boni Guy-Martial Kouame, Bi Foua Jonas Vanie, Amena Guy Germaine Niamke, Kouzahon Colombe Jeannine Lohore, Aké Chibrou Bénédicte Yapo-Kee, Youzan Ferdinand Djohan
{"title":"[Diagnosis of significant hepatic fibrosis in patients with chronic hepatitis B: another simple, effective and inexpensive method].","authors":"Boni Guy-Martial Kouame, Bi Foua Jonas Vanie, Amena Guy Germaine Niamke, Kouzahon Colombe Jeannine Lohore, Aké Chibrou Bénédicte Yapo-Kee, Youzan Ferdinand Djohan","doi":"10.1684/abc.2025.1964","DOIUrl":"10.1684/abc.2025.1964","url":null,"abstract":"<p><p>Early diagnosis of liver fibrosis remains a challenge. The aim of this study was to compare the performance of the GPR, APRI and FIB-4 scores in the diagnosis of significant fibrosis in chronic hepatitis B. This was a 6-month cross-sectional study. Patients were aged 18 and over, had a FibroScan® and had venous blood samples taken. 133 patients were included. The mean FibroScan® value was 5.33 ± 0.47 kPa, with 26.32% showing significant fibrosis (>7.2 kPa). The GPR score had a sensitivity of 80% compared with 48.57% and 51.42% respectively for the APRI and FIB-4 scores. However, its specificity was lower (51.02%) compared with the APRI (77.55%) and FIB-4 (81.63%) scores. The area the ROC curve of the GPR score (0.760) was higher than that of the APRI (0.712) and FIB-4 (0.724) scores in predicting significant fibrosis (p < 0.05). The GPR score is more accurate for assessing liver fibrosis in chronic hepatitis B in sub-Saharan Africa.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"83 2","pages":"176-84"},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143805191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}